Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Citius Pharmaceuticals Inc has a consensus price target of $4.67 based on the ratings of 3 analysts. The high is $6 issued by EF Hutton on August 19, 2024. The low is $4 issued by HC Wainwright & Co. on May 31, 2024. The 3 most-recent analyst ratings were released by EF Hutton on August 19, 2024, August 8, 2024, and August 5, 2024, respectively. With an average price target of $6 between EF Hutton, there's an implied 970.09% upside for Citius Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Citius Pharma (NASDAQ:CTXR) was reported by EF Hutton on August 19, 2024. The analyst firm set a price target for $6.00 expecting CTXR to rise to within 12 months (a possible 970.09% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Citius Pharma (NASDAQ:CTXR) was provided by EF Hutton, and Citius Pharma maintained their buy rating.
There is no last upgrade for Citius Pharma
There is no last downgrade for Citius Pharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Pharma was filed on August 19, 2024 so you should expect the next rating to be made available sometime around August 19, 2025.
While ratings are subjective and will change, the latest Citius Pharma (CTXR) rating was a maintained with a price target of $6.00 to $6.00. The current price Citius Pharma (CTXR) is trading at is $0.56, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.